Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Short-term Investments: 2009-2025

Historic Short-term Investments for Amicus Therapeutics (FOLD) over the last 16 years, with Sep 2025 value amounting to $73.3 million.

  • Amicus Therapeutics' Short-term Investments rose 354.93% to $73.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.3 million, marking a year-over-year increase of 354.93%. This contributed to the annual value of $36.2 million for FY2024, which is 7.68% down from last year.
  • According to the latest figures from Q3 2025, Amicus Therapeutics' Short-term Investments is $73.3 million, which was up 1.37% from $72.3 million recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Short-term Investments peaked at $237.3 million during Q4 2021, and registered a low of $16.1 million during Q3 2024.
  • Over the past 3 years, Amicus Therapeutics' median Short-term Investments value was $50.7 million (recorded in 2024), while the average stood at $51.3 million.
  • In the last 5 years, Amicus Therapeutics' Short-term Investments crashed by 77.98% in 2023 and then soared by 354.93% in 2025.
  • Over the past 5 years, Amicus Therapeutics' Short-term Investments (Quarterly) stood at $237.3 million in 2021, then plummeted by 38.99% to $144.8 million in 2022, then crashed by 72.92% to $39.2 million in 2023, then fell by 7.68% to $36.2 million in 2024, then surged by 354.93% to $73.3 million in 2025.
  • Its last three reported values are $73.3 million in Q3 2025, $72.3 million for Q2 2025, and $68.9 million during Q1 2025.